Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.40 Insider Own16.06% Shs Outstand103.91M Perf Week-1.80%
Market Cap678.53M Forward P/E- EPS next Y-1.96 Insider Trans0.00% Shs Float87.22M Perf Month-3.12%
Income-192.41M PEG- EPS next Q-0.50 Inst Own74.08% Short Float12.43% Perf Quarter33.81%
Sales0.00M P/S- EPS this Y18.60% Inst Trans4.55% Short Ratio5.06 Perf Half Y-30.83%
Book/sh2.30 P/B2.84 EPS next Y0.27% ROA-62.65% Short Interest10.84M Perf Year-40.37%
Cash/sh2.56 P/C2.55 EPS next 5Y- ROE-74.94% 52W Range3.67 - 13.50 Perf YTD11.05%
Dividend Est.- P/FCF- EPS past 5Y15.33% ROI-69.90% 52W High-51.63% Beta1.57
Dividend TTM- Quick Ratio7.09 Sales past 5Y-6.78% Gross Margin- 52W Low77.93% ATR (14)0.46
Dividend Ex-Date- Current Ratio7.09 EPS Y/Y TTM1.94% Oper. Margin0.00% RSI (14)47.93 Volatility4.88% 6.74%
Employees164 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.36 Target Price17.00
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-11.53% Payout- Rel Volume0.00 Prev Close6.53
Sales Surprise- EPS Surprise-13.66% Sales Q/Q- EarningsFeb 26 BMO Avg Volume2.14M Price6.53
SMA20-0.76% SMA50-5.24% SMA200-22.90% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Feb-26-24Downgrade Robert W. Baird Outperform → Neutral $14 → $8
Feb-08-24Initiated Citigroup Buy $11
Dec-11-23Downgrade Wedbush Outperform → Neutral $5
Dec-08-23Initiated JP Morgan Overweight $18
Apr-28-23Initiated Robert W. Baird Outperform $20
Mar-27-23Resumed H.C. Wainwright Buy $28
Dec-14-22Initiated Needham Buy $24
Jun-28-22Initiated Guggenheim Buy $15
Oct-11-21Initiated H.C. Wainwright Buy $25
Jun-09-21Resumed Jefferies Buy $20
Apr-09-24 09:00AM
Mar-13-24 07:06AM
Feb-28-24 04:32AM
Feb-26-24 08:00AM
Feb-22-24 02:30PM
07:00AM Loading…
Feb-14-24 07:00AM
Feb-05-24 09:00AM
Jan-09-24 08:00AM
Jan-02-24 08:00AM
Dec-11-23 07:55AM
Dec-09-23 01:30PM
Dec-07-23 09:00AM
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-02-23 09:00AM
12:30PM Loading…
Oct-14-23 12:30PM
Aug-13-23 08:51AM
Aug-08-23 08:00AM
Jul-10-23 07:35PM
Jun-09-23 04:01PM
Jun-07-23 09:00AM
Jun-06-23 08:25PM
Jun-03-23 02:15PM
May-23-23 08:00AM
May-09-23 08:00AM
Apr-17-23 09:00AM
Apr-12-23 08:00AM
Mar-14-23 08:00AM
Feb-01-23 08:00AM
11:03AM Loading…
Jan-11-23 11:03AM
Jan-09-23 08:00AM
Jan-05-23 08:00AM
Dec-11-22 05:30PM
Dec-05-22 08:00AM
Nov-28-22 04:15PM
Nov-14-22 07:00AM
Nov-09-22 08:00AM
Nov-03-22 09:05AM
Oct-26-22 07:00AM
Aug-14-22 12:21PM
Aug-09-22 07:00AM
Aug-04-22 11:22AM
Jun-20-22 11:09AM
Jun-16-22 04:01PM
Jun-13-22 09:48PM
Jun-10-22 07:00AM
Jun-06-22 10:15AM
Jun-02-22 08:00AM
May-12-22 10:00AM
May-10-22 07:00AM
May-06-22 08:00AM
Apr-11-22 07:00AM
Mar-29-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 05:10PM
Feb-01-22 05:29AM
Jan-05-22 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Nov-02-21 07:00AM
Oct-29-21 09:46AM
Oct-12-21 07:59PM
Oct-07-21 09:00AM
Oct-01-21 07:00AM
Aug-16-21 07:00AM
Jul-27-21 07:00AM
Jul-13-21 11:11AM
Jun-29-21 07:00AM
Jun-15-21 11:37AM
May-26-21 07:00AM
May-12-21 07:00AM
May-03-21 07:00AM
Apr-06-21 07:00AM
Mar-17-21 02:27AM
Mar-16-21 07:00AM
Feb-22-21 07:00AM
Feb-18-21 07:00AM
Feb-11-21 07:00AM
Dec-04-20 05:16PM
Dec-01-20 11:08PM
Nov-30-20 04:01PM
Nov-20-20 07:00AM
Nov-18-20 09:00AM
Nov-12-20 04:30PM
Nov-09-20 07:00AM
Nov-05-20 07:00AM
Oct-26-20 07:00AM
Apr-01-20 01:42AM
Nov-13-19 06:22PM
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLC10% OwnerJun 09 '23Buy12.00800,0009,600,0003,272,124Jun 13 04:07 PM